Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease

盐皮质激素受体在糖尿病心血管疾病中的作用

• 批准号: 7788076
• 负责人: Gail Kurr Adler
• 金额: $ 62.93万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-15 至 2012-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7788076
• 关键词: Acute; Address; Adenosine; Aftercare; Albuminuria; Aldosterone; Amlodipine; Angiotensin II; Angiotensin II Receptor; Angiotensin-Converting Enzyme Inhibitors; Animals; Blindness; Blood; Blood Circulation; Blood Pressure; Blood Vessels; Blood flow; Cardiac; Cardiovascular system; Chemicals; Chronic; Clinical Data; Clinical Research; Coronary; Corticotropin; Data; Diabetes Mellitus; Double-Blind Method; Echocardiography; Enalapril; Enzyme Inhibition; Fibrosis; Functional disorder; Goals; Health; Heart; Heart failure; Hormones; Human; Hydrochlorothiazide; Hypertension; Image; Individual; Inflammation; Injury; Kidney; Kidney Failure; Left; Leg; Measures; Mediating; Mediator of activation protein; Mineralocorticoid Receptor; Myocardial; Myocardial perfusion; Myocardium; Non-Insulin-Dependent Diabetes Mellitus; Patients; Peptidyl-Dipeptidase A; Perfusion; Placebos; Positron-Emission Tomography; Potassium; Randomized; Receptor Activation; Renal Circulation; Renal Plasma Flow; Research; Rest; Role; Spironolactone; Stress; Stroke; Testing; Tissues; Vascular Diseases; Ventricular; Work; cardiovascular injury; chemokine; db/db mouse; diabetic; diabetic cardiomyopathy; effective therapy; eplerenone; heart circulation; heart function; improved; improved functioning; kidney vascular structure; pre-clinical; preclinical study; prevent; prospective; public health relevance; response; treatment duration; vascular inflammation; vasoactive agent

DESCRIPTION (provided by applicant): Diabetes mellitus is often associated with significant cardiovascular injury. Recent data provide support for the hypothesis that activation of mineralocorticoid receptor (MR) contributes to diabetic vascular injury, though the mechanisms are uncertain. Consistent with this hypothesis, our pre-clinical studies in diabetic db/db mice demonstrate that blockade of MR reduces albuminuria and decreases glomerular and tubulointerstitial injury. Our studies in hypertensive, angiotensin II (ANGII)-infused animals demonstrate that MR antagonists reduce vascular inflammation and cardiac and renal injury. Furthermore, our clinical studies show that short-term treatment with the MR antagonist eplerenone improves myocardial perfusion reserve as compared to treatment with hydrochlorothiazide (HCTZ) in subjects with diabetes receiving angiotensin-converting enzyme (ACE) inhibition therapy. This observation is important as it suggests that MR antagonists are not working via a classical renal effect, but via an additional, volume control-independent mechanism. This proposal will test the hypothesis that activation of the MR contributes to progression of vascular disease in subjects with type 2 diabetes mellitus receiving ACE inhibitor therapy, and consequently, MR antagonists exert beneficial effects by reducing vascular dysfunction and injury, inhibiting ANGII vascular effects, and improving coronary circulatory and cardiac function. To address this hypothesis we will perform a prospective randomized, double-blind study in subjects with type 2 diabetes mellitus and hypertension receiving chronic ACE inhibitor therapy. Subjects will be randomized to one of three treatments: 1) MR antagonist spironolactone; 2) HCTZ plus potassium; and 3) placebo. We will determine the effects of MR blockade in two specific aims. Aim 1 will assess cardiac function by measuring myocardial perfusion reserve and diastolic function and Aim 2 will assess renovascular function. These studies will provide new information about the mechanisms by which MR antagonists reduce diabetic cardiovascular injury, with the goal of introducing new, effective treatments of cardiovascular injury in individuals with diabetes through the addition of MR blockade to ACE inhibitor therapy. PUBLIC HEALTH RELEVANCE: Diabetes is an important cause of injury to blood vessels. Vascular injury leads to many health problems including heart damage, kidney failure, stroke, blindness and poor circulation in the legs. It is not completely known how diabetes causes this damage or how to prevent the damage. Recent studies in animals and humans suggest that a blood hormone (chemical) known as aldosterone causes damage to blood vessels. The goal of this research is to determine whether blocking the actions of aldosterone improves the function of vessels in the hearts and kidneys of patients with type 2 diabetes and whether this leads to improvements in heart function. If successful, this research will provide doctors with information about a new way to treat individuals with diabetes who have injuries to their blood vessels, heart and kidneys.

描述（由申请人提供）：糖尿病通常与严重的心血管损伤有关。最近的数据支持了矿化皮质激素受体（MR）激活导致糖尿病血管损伤的假设，尽管其机制尚不确定。与这一假设一致，我们在糖尿病db/db小鼠中的临床前研究表明，MR阻断可减少蛋白尿，减少肾小球和小管间质损伤。我们对高血压、血管紧张素II （ANGII）输注的动物的研究表明，MR拮抗剂可以减少血管炎症和心脏和肾脏损伤。此外，我们的临床研究表明，在接受血管紧张素转换酶（ACE）抑制治疗的糖尿病患者中，与氢氯噻嗪（HCTZ）治疗相比，短期使用MR拮抗剂eplerenone可改善心肌灌注储备。这一观察结果很重要，因为它表明MR拮抗剂不是通过经典的肾脏效应起作用，而是通过另一种不依赖于体积控制的机制起作用。本研究将验证在接受ACE抑制剂治疗的2型糖尿病患者中，MR的激活有助于血管疾病的进展，因此MR拮抗剂通过减少血管功能障碍和损伤、抑制ANGII血管作用、改善冠状动脉循环和心脏功能发挥有益作用。为了验证这一假设，我们将在接受慢性ACE抑制剂治疗的2型糖尿病和高血压患者中进行一项前瞻性随机双盲研究。受试者将随机接受三种治疗之一：1)MR拮抗剂螺内酯；2) HCTZ +钾；3)安慰剂。我们将在两个具体目标中确定MR阻断的效果。Aim 1将通过测量心肌灌注储备和舒张功能来评估心功能，Aim 2将评估肾血管功能。这些研究将为MR拮抗剂减少糖尿病心血管损伤的机制提供新的信息，目的是通过在ACE抑制剂治疗中添加MR阻断剂，为糖尿病患者引入新的、有效的心血管损伤治疗方法。公共卫生相关性：糖尿病是血管损伤的重要原因。血管损伤会导致许多健康问题，包括心脏损伤、肾衰竭、中风、失明和腿部循环不良。目前还不完全清楚糖尿病是如何引起这种损害的，也不知道如何预防这种损害。最近对动物和人类的研究表明，一种叫做醛固酮的血液激素（化学物质）会对血管造成损害。本研究的目的是确定阻断醛固酮的作用是否能改善2型糖尿病患者心脏和肾脏血管的功能，以及这是否会导致心脏功能的改善。如果成功，这项研究将为医生提供一种治疗血管、心脏和肾脏受损的糖尿病患者的新方法。